It is well known among surgeons, anesthesiologists, and intensivists caring for pediatric patients undergoing cardiac surgery that perioperative bleeding and blood product transfusion are significant challenges. Both patient and operative factors influence the risk of bleeding in this population. Effective and efficient coagulation management increasingly has become important, as the risks of transfusion on short-and long-term outcomes have become evident. Transfusion is associated with both nonimmune-and immune-mediated reactions including infection, hemolytic reactions, allergic reactions, transfusion-related acute lung injury, transfusion-associated graft-versus-host disease, and transfusion-related immunomodulation. Increased morbidity and mortality are associated with red cell transfusion in the pediatric cardiac surgery population. 1 Patients with congenital heart disease who undergo multiple operations with repeated exposures to blood products generate alloantibodies, which can become problematic should the patient eventually require cardiac transplantation. Allosensitization leads to longer waiting time and pretransplant mortality, as well an increased risk of early death after transplant. 2, 3 It also is clear that wide variation in transfusion strategy exists between centers, 4 and therapy for postbypass coagulopathy largely has been empiric. 5 Much of this variation is attributable to the patient population, the surgical procedure, and the need for and conduct of cardiopulmonary bypass (CPB). The population of pediatric patients undergoing surgery for congenital heart disease is heterogeneous. These patients vary by age, size, presence and degree of cyanosis, presence and degree of polycythemia, preoperative anticoagulation, and other comorbidities. Surgical procedures differ in the need for CPB, the degree of hypothermia, the use of techniques such as selective cerebral perfusion or deep hypothermic circulatory arrest, and whether the patient has undergone a previous sternotomy. In addition, the bypass circuit priming volumes produce different degrees of hemodilution and dilution of coagulation factors depending on the size of the patient, with neonates experiencing the greatest dilutional effect. A similar effect is seen in patients undergoing a partial or full exchange transfusion for sickle cell disease. Multiple management strategies must exist to care for very different patients undergoing a variety of procedures, making standardization of care difficult.
Current areas of interest include the use of fresh whole blood to prime the CPB circuit, the use of antifibrinolytics, the use of intraoperative point-of-care (POC) testing, the role of goal-directed transfusion algorithms or guidelines, the emerging role of factor concentrates in the treatment of postbypass coagulopathy, and antithrombin supplementation in neonates and infants for CPB.
FRESH WHOLE BLOOD
The use of fresh whole blood (less than 48 hours from donation to transfusion) has been demonstrated to reduce bleeding in patients younger than 2 years old undergoing complex operations for congenital heart disease, 6 and its use recently has been reported to reduce the number of blood donor exposures. 7 Other studies, however, have not shown a benefit of priming with fresh whole blood compared with reconstituted blood (packed red blood cells and fresh frozen plasma). 8 Gruenwald and colleagues 9 compared clinical outcomes in patients receiving reconstituted fresh whole blood (red cells, plasma, and platelets from a single donor) versus standard component therapy; findings included decreased chest tube output at 24 hours, decreased inotropic score at 24 hours, and decreased time to extubation with reconstituted fresh whole blood. Other advantages with reconstituted whole blood were greater platelet count at the end of bypass, a decrease in donor exposures, and younger age of blood products. 9 Significant challenges exist in obtaining fresh whole blood for pediatric cardiac surgery. Jobes and colleagues 7 emphasize that careful planning and communication between the donation center, blood bank, and surgical service is required to make these products available. Leukocyte reduction is now available for fresh whole units, which should decrease allosensitization. 8 Reconstituted fresh whole blood may preserve platelet function, because these units are isolated and stored at room temperature. The platelets in fresh whole blood may have decreased function due to storage at 4 C.
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ANTIFIBRINOLYTICS Aprotinin, a serine protease inhibitor, and epsilonaminocaproic acid (EACA) and tranexamic acid (TXA) are efficacious in reducing bleeding and transfusion in pediatric patients undergoing cardiac surgery. After aprotinin became unavailable in most institutions, many centers replaced it with EACA or TXA. Dosing strategies are variable for each drug and are not always based on pharmacokinetic data. 10 The dosing regimen for EACA used at Texas Children's Hospital is a loading dose of 75 mg/kg to the patient, 75 mg/kg to the bypass prime, and a 75 mg/kg/h infusion, based on pharmacokinetic data from Ririe and colleagues. 11 Recently, neonatal EACA dosing has been modified to reflect reduced clearance with a loading dose of 40 mg/ kg, an infusion of 30 mg/kg/h, and a concentration of 100 mg/L in the bypass prime. 12 TXA dosing schema based on pharmacokinetic modeling and designed to produce a low, intermediate, or high plasma concentrations in neonates and infants<2 months of age, infants 2 to 12 months, and children >12 months of age recently have been reported. 13 These dosing recommendations reflect age-related differences in clearance, and like the neonatal dosing modification for EACA, are designed to produce a specified concentration in the bypass prime, rather than a weight-based bolus. 10 Although all 3 antifibrinolytics reduce bleeding and transfusion in pediatric cardiac surgery patients, both EACA and TXA are reported to be associated with increased bleeding compared with aprotinin, eg, increased rates of administration of recombinant activated factor VII (rFVIIa), surgical re-exploration, and transfusion. 14, 15 
MONITORING OF COAGULATION STATUS
Coagulation status can be analyzed with laboratory tests and POC tests. Standard laboratory tests include a platelet count, prothrombin time, partial thromboplastin time, and fibrinogen concentration. The laboratory tests are helpful for defining coagulopathy, but results can take so much time that they are not useful for guiding treatment. POC tests include the activated clotting time (ACT), used to monitor heparin effect, thromboelastography (TEG), and rotational thromboelastometry (ROTEM; TEM Systems, Inc, Research Triangle Park, NC), used to identify and characterize coagulopathy, and platelet function tests, including the Sonoclot analyzer (Sienco, Inc, Boulder, Colo), PFA-100 (Siemens Medical Solutions USA, Inc, Malvern, Pa), and MultiPlate (Roche Diagnostics International, Ltd, Rotkreuz, Switzerland) platelet aggregometer. 5 The advantage of POC tests is that the result and/or tracing is available in real time. The ACT is easy to perform, inexpensive, and provides a simple way to monitor the effects of heparin.
TEG and ROTEM are being used increasingly to determine the nature of the coagulopathy (Figure 1 ). Both tests provide a real-time assessment of the multiple components of hemostasis including platelet activity, coagulation factors, fibrinogen, and fibrinolysis. Both TEG and ROTEM have been demonstrated to decrease transfusion requirements in pediatric cardiac surgery. [16] [17] [18] Furthermore, specific ROTEM analysis during CPB before hemoconcentration allows the earlier detection of coagulation abnormalities. 19 These tests can lead to improved goal-directed planning and therapy. Platelet function tests have not been used widely in pediatric cardiac surgery. More importantly, these POC tests provide direction for treatment, instead of empiric therapy with platelets or cryoprecipitate, as has been standard practice. 20 
GOAL-DIRECTED TRANSFUSION THERAPY
Goal-directed transfusion algorithms have been used extensively in adult cardiac surgery and have been demonstrated to decrease transfusion, improve clinical outcomes, and standardize practice. Many of these algorithms are based on POC tests such as TEG or ROTEM. 21 Goaldirected algorithms also have been described for pediatric cardiac surgery based on standard laboratory coagulation analysis 22 and on POC testing. 17, 18, 23 The use of these algorithms has been associated with reduced transfusion and reduced stay in the intensive care unit. 18 The described ROTEM-based algorithms differed in the parameters used for decision-making. For example, Nakayama and colleagues 18 and Faraoni and colleagues 23 predominantly used EXTEM (thromboelastometry with tissue factor) A10 and FIBTEM (thromboelastometry with cytochalasin D) A10, whereas Romlin and colleagues 17 used FIBTEM MCF and HEPTEM (thromboelastometry with heparinase) MCF and CT. The A10 is the amplitude after 10 minutes, the MCF is the maximum clot firmness, and the CT is clotting time. These algorithms also differ in the hemostatic therapy administered in response to clinical bleeding and abnormal thromboelastometry values; some groups used all blood products, whereas others used factor concentrates.
COAGULATION FACTOR CONCENTRATES
Goal-directed therapy using POC testing with coagulation factor concentrate-based algorithms has been used safely and effectively to treat coagulopathy and reduce transfusion in adult cardiac surgery patients, 21 but there are a paucity of data in children. Fibrinogen concentrate has been demonstrated to be as effective and safe as cryoprecipitate in children undergoing cardiac surgery, 24 and fibrinogen concentrate is recommended for fibrinogen replacement in thromboelastometry-based transfusion algorithms 17, 23 for the treatment of postbypass coagulopathy in children. Recombinant activated factor VII has been used off-label in pediatric patients undergoing cardiac surgery to treat coagulopathy. The potential thrombotic risk associated with the drug should limit its use to rescue therapy for massive, refractory bleeding. 25 The use of 3-factor prothrombin complex concentrate (PCC) in 6 infants with ongoing bleeding after CPB has been reported by Jooste and colleagues. 26 The risk of thrombotic complications is a concern with the use of factor concentrates; care should be taken to avoid the coadministration of rFVIIa and PCC containing factor VII.
ANTITHROMBIN
Heparin covalently binds to antithrombin, a glycoprotein that is made in the liver, and causes a 2000-to 4000-fold increase in thrombin inhibition, which enables systemic anticoagulation for CPB. There is significant variability in antithrombin levels in neonates, infants, and children that can be attributed to age, immaturity of the coagulation system, inflammation, and liver dysfunction. Patients with low levels of antithrombin have lower heparin efficacy, and more heparin is required to maintain an adequate ACT. In addition, lower antithrombin levels result in increased thrombin generation on CPB, a risk factor for perioperative coagulopathy and/or thrombosis. 27 In congenital heart surgery, antithrombin levels often are augmented by the administration of fresh-frozen plasma. Large volumes of fresh-frozen plasma, however, are required to increase the antithrombin level even modestly. Recombinant antithrombin is available in the United States and can be used specifically to increase antithrombin levels and improve heparin efficacy and decrease thrombin generation on CPB. Randomized controlled trials of preoperative antithrombin supplementation in adults undergoing cardiac surgery with the use of CPB have been published, and there has been one pilot study of antithrombin replacement in neonates undergoing CPB. 28, 29 Antithrombin replacement currently is used in pediatric patients on extracorporeal life support, and its use has increased heparin efficacy and reduced dosing in these patients. 30 
COMMUNICATION
Communication and teamwork is required for safe treatment for coagulopathy in pediatric cardiac surgery. POC testing, goal-directed transfusion algorithms, and factor concentrate availability improve the speed and efficiency of treatment of bleeding. However, a dialogue between the surgeon and anesthesiologist regarding the extent of bleeding, the presence of surgical bleeding, the results of POC testing, the status of clot formation, and the administration of blood products and and/or factor concentrates is critical to avoid undertreatment or overtreatment of coagulopathy with potential catastrophic thrombotic complications.
In addition, on arrival to the intensive care unit, a full assessment of the patient's hemostatic profile, including blood products given, intraoperative tests performed, and factor concentrates given, should be reported by the anesthesiologist to the entire intensive care team in a structured manner. The effective transfer of this information is necessary to avoid potentially life-threatening hypercoagulability and should be a standard element in the handover.
POSTBYPASS BLEEDING IN NEONATES
The avoidance and treatment of postbypass coagulopathy in the neonate continues to be a significant and pervasive challenge for those caring for patients undergoing congenital heart surgery. A greater risk of bleeding due to an immature coagulation system, large dilutional effect due to the volume of the CPB circuit compared with the neonatal blood volume, and often-complex operations with extensive suture lines and often performed at moderate to deep hypothermia. In a recent retrospective review of 169 neonates undergoing complex congenital heart surgery, patients in the upper quartile of postbypass bleeding had an increased risk of postoperative dialysis, extracorporeal membrane oxygenation, and in-hospital mortality. 
CONG
Avoidance of postbypass coagulopathy in neonates begins preoperatively. The bypass circuit can be miniaturized by the use of smaller-caliber and shorter bypass tubing, as well as a smaller oxygenator and hemofilter. Vacuumassisted drainage also can be used. These measures can decrease the amount of priming volume and therefore decrease the amount of dilution of coagulation factors. 32 In addition, although there are institutional preferences and availability issues regarding the use of fresh whole blood or reconstituted whole blood for bypass circuit priming, [6] [7] [8] [9] it is critical for plasma to be added to the pump to maintain an adequate concentration of coagulation factors. The use of antifibrinolytic agents are warranted in this population, as well, to reduce the risk of fibrinolysis and the requirement for blood transfusion. 1, 33 POC testing such as ACT and ROTEM or TEG should be considered to guide blood product administration. Recombinant activated factor VII is not recommended for routine prophylaxis against bleeding in neonates undergoing congenital heart surgery, but it should be considered as rescue therapy after standard treatment has been carried out. 25, 34, 35 The Congenital Cardiac Anesthesia Society rFVIIa Task Force agrees on an initial dose of 90 mg/kg based on previous studies. 25 Future directions in the prevention and treatment of postbypass coagulopathy in the neonate include intense heparin management with antithrombin level monitoring and replacement 28, 29, 36 and the use of individualized anticoagulation management systems that have been shown to decrease blood product administration in infants undergoing cardiac surgery using CPB. 37 Although there is no evidence to support the use of newer factor concentrates such as 3-and 4-factor PCCs and fibrinogen concentrate in this population, 34 there is ex vivo evidence that 3-and 4-Factor PCC augments thrombin generation in neonatal plasma after CPB and may be a useful adjunct to standard blood component therapy. 38, 39 The potential for creating a hypercoagulable state exists, and translocated coronary arteries and Blalock-Taussig shunts, for example, may be at risk. Care should be taken when administering these new medications. Combining PCCs and rFVIIa could create life-threatening thrombosis and, in our opinion, should be avoided. ROTEM, TEG, and/or standard coagulation laboratory tests should be followed.
CONCLUSIONS
Coagulation and transfusion management in pediatric cardiac surgery remain challenges in the care of these complex patients, and there is not one strategy that can be applied to every patient. With the multiple new monitoring tests and pharmacologic treatments for coagulopathy, additional research is needed to optimize the approach to the treatment of postbypass coagulopathy with both blood products and factor concentrates and to determine their effect on outcomes.
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